New trial
Phase I Study of Ruxolitinib Plus Abemaciclib for Patients With Primary or Post-PV/ET Myelofibrosis
- Trial ID
- NCT05714072 on ClinicalTrials.gov
- Cancer type
- Hematologic Cancers
- Location
- 7 Locations
- Published in
- New in Oncology - May 21, 2025
Memorial Sloan Kettering is assessing the safety and efficacy of combining ruxolitinib (a JAK1 inhibitor) with abemaciclib (a CDK4/6 inhibitor) in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
More on NCT05714072
-
Trial result · Apr 30, 2026
Ruxolitinib + Abemaciclib (CDK4/6) Shows 44% SVR35 in Rux-Inadequate-Response Myelofibrosis
More in other blood cancers and transplant
-
Trial result · Aug 13, 2026 · NCT04904588
Standard-dose PTCy enables mismatched-donor HCT but carries substantial early infection burden -
Trial result · Aug 6, 2026 · NCT05388123
Low-dose vemurafenib (BRAF V600E inhibitor) + rituximab drives 73% CR with zero grade 3-4 AEs in HCL -
Trial result · Aug 6, 2026 · NCT02113982
Tagraxofusp (CD123-directed cytotoxin) in BPDCN delivers 71%–90% ORR across trials—HSCT bridge drives survival -
New trial · Jun 25, 2026 · NCT07634536
Phase 2 automated VMAT-based TMLI conditioning refines marrow / lymphoid-targeted irradiation for allo-HCT. -
New trial · Jun 25, 2026 · NCT07572006
Phase 1 JNJ-95804306 (no disclosed MOA/target) in relapsed/refractory AML/MDS and CLL/SLL